TSS
CADL icon

Two Sigma Securities’s Candel Therapeutics CADL Stock Holding History

Two Sigma Securities’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-16,510
Closed -$24.3K – 3013
2023
Q4 		$24.3K Buy
+16,510
New +$16K ﹤0.01% 2693

Other funds holding CADL

NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Securities's CADL Position: Q1 2024 in Review

Two Sigma Securities sold out of Candel Therapeutics (CADL) in Q1 2024, closing a stake of 16,510 shares — an estimated $24.3K sold.

Two Sigma Securities first reported a position in CADL in Q4 2023 and held it in 1 quarter. The position peaked at $24.3K in Q4 2023. 20 funds tracked by Wall St. Rank hold CADL as of Q1 2024.

  • Two Sigma Securities reported no remaining Candel Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Two Sigma Securities sold 16,510 Candel Therapeutics shares in Q1 2024, an estimated $24.3K.
  • Two Sigma Securities first reported a position in Candel Therapeutics in Q4 2023 and held it in 1 quarter.
  • Two Sigma Securities's Candel Therapeutics position peaked at $24.3K in Q4 2023.
  • 20 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2024.

Based on Two Sigma Securities's 13F filing for Q1 2024, filed 15 May 2024.